SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus shares are drawing attention amid a steep, volatile selloff, with traders blaming share dilution from equity and warrant offerings, a rich valuation, and the cost and execution risks of expanding enrichment capacity. Bulls counter that DOE and commercial fuel contracts support the longer-term domestic nuclear-fuel and HALEU opportunity, while bearish traders question when that growth will translate into results.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report has traders focused on BRIUMVIs sales momentum and the possibility of stronger guidance. The community also points to heavy call activity and short interest, while debating whether the rally reflects earnings positioning and momentum or unconfirmed buyout speculation; upcoming subcutaneous BRIUMVI data is another catalyst in view.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over its potential effect on sales. Traders weigh the rivals dosing advantages against PAPZIMEOS commercial head start, established payer access and stronger first-year response data, while also watching Precigens upcoming earnings for evidence of continued uptake.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity raise and stock-funded Elisity acquisition have put dilution and capital allocation at the center of discussion as shares sell off. Some traders see the deal as extending the company into cybersecurity and broader quantum infrastructure, while others question its value per share and want evidence that acquisitions and quantum programs can translate into recurring revenue.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios post-earnings selloff follows a Q3 beat and higher full-year outlook, as its Q4 organic growth guidance signaled a slowdown from the prior quarter. Traders are divided between viewing the drop as an overreaction with bounce potential and waiting for the stock to stabilize as investors reassess the growth outlook.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases selloff is being tied to Q3 results that beat on headline EPS but showed weaker trading revenue and operating performance, with much of reported profit attributed to gains on crypto holdings; the Binance hack and broader crypto-market weakness have added pressure. Traders disagree on whether the breach could send users to Coinbase or deepen concerns about exchange security and crypto demand.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarnas steep post-earnings slide and persistent weak trading dominate the discussion, with traders debating whether concerns about guidance, profitability and ongoing selling pressure explain the decline or whether the stock is oversold ahead of Q3 results. Bulls cite Apple and payments partnerships and longer-term BNPL growth, while frustrated holders question why the shares keep lagging.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

The European Lithium acquisition and resulting CRML share issuance are driving debate, with some traders concerned about dilution and potential selling pressure while others see the added cash and assets, including greater ownership of Tanbreez, as a positive. High-borrow-cost and short-squeeze speculation is also prominent, though traders disagree on whether it will lead to sustained buying.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 78,059.66839082 USD and is up 0.67 over the last 24 hours. It is currently trading on 12773 active market(s) with $13,095,082,899.62 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

The massive Binance hack and the exchanges resumption of withdrawals have put crypto security, customer outflows, and potential market contagion at the center of Bitcoin discussion. Traders are divided: bears warn of further selling and exchange-liquidity risks, while bulls argue Bitcoins resilience through the incident supports a recovery.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,023,844,090.614844 with 95,023,861,343.880544 in circulation. The last known price of TRON is 0.3125405 USD and is up 1.67 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,085,916,839.31 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRONs steady price action and relative resilience versus other cryptocurrencies are drawing attention, with traders debating whether consolidation signals another breakout or a corrective pullback. Some also point to the networks role in stablecoin transfers as support for the longer-term bullish case, while others remain frustrated by its subdued moves.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares Rise as Biotech Pivots Toward AI-Driven Pharmaceutical Automation

Pharmaceutical manufacturing is one of the most heavily regulated industries in the world. Every batch, every deviation, and every cleaning record must be documented and defensible under audit. This process has traditionally been manual, slow, and expensive. Companies capable of automating these workflows with AI stand to save significant time while reducing compliance risk. Today, one clinical-stage biotech announced a strategic deal to bring that automation to the physical factory floor.&nbsp;Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on the ...

Micro-Cap Stuns Market with Billion-Dollar Pipeline Valuation

It&#8217;s not often that a micro-cap company with a market value of around $40 million announces a third-party valuation of its drug development pipeline at $1.7 billion, 45% of which it owns. But that&#8217;s exactly what was revealed in a press release this morning. As expected, the stock reacted swiftly and rallied on the news.As mentioned, shares of Oncotelic Therapeutics <a href="https://www.allpennystocks.com/stockquote/OTLC" target="_blank">(OTCQB: OTLC)</a> are surging on news that the company announced a major milestone after its joint venture partner, GMP Bio, completed an independent third-party valuation of its drug development pipeline. The assessment, performed by Frost &amp; Sullivan (Hong Kong), values the pipeline at roughly $1.7 billion, translating to an estimated $765 million potential value for Oncotelic based on its 45% ownership stake. The company noted that this figure is forward-looking and non-binding, and it does not reflect fair value under U.S. GAAP. To support upcoming financial disclosures, a separate ASC-compliant valuation is already underway. If that analysis indicates a materially higher carrying value, Oncotelic may adjust future financial statements to reflect its increased minority interest, potentially boosting total assets and shareholder equity, pending the outcome of the review and applicable accounting standards.The joint venture has made significant progress across its therapeutic programs, including moving OT-101 into a Phase 3 PDAC trial and multiple Phase 2 combination studies. Meanwhile, GMP Bio is actively expanding its Deciparticle&#8482; nanomedicine platform, with several candidates advancing toward clinical development. Its San Diego GMP-licensed manufacturing facility is now fully operational and ready to support upcoming trials. Looking ahead, the JV is exploring a possible IPO on the Hong Kong Stock Exchange targeted for late 2026. While market conditions and regulatory approval will ultimately dictate the timing, Oncotelic views the strong pipeline valuation as a key indicator of the strategic value behind the potential offering.&#8220;This represents one of the most significant milestones in Oncotelic&#8217;s history,&#8221; said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics. &#8220;The independent valuation recognizes the multi-year scientific and clinical progress achieved through our GMP Bio joint venture and affirms the long-term potential of OT-101 and our Deciparticle&#8482; nanomedicine platform.&#8221;Shares of OTLC are currently trading up 26.15% at $0.09524 in mid-morning trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4012/micro-cap-stuns-market-with-billion-dollar-pipeline-valuation'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

Oncotelic Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$OTLC - Bear set the looks bloody here! - Get ready to see the Bulls in chart - Momentum and Accumulation Response

MatWizard

$OTLC  Insider buys show Trieu also bought 1,044, 990 at .017 and 312,000 at .0185 filed today.

Chris Ruel

$OTLC Bobby W Phd Sandage  258,171 
William N Shiebler  10,000 
Per Olof Soderberg Director - [D]  179,256 179,256
Saran Saund CHIEF BUSINESS OFFICER - [O]  16,457,480 16,457,480
William D Schwieterman President and CEO, Director - [D] [O]  625,747 625,747
Shah Amit B. CFO - [O]  378,837 378,837
Vuong Trieu CHAIRMAN AND CEO, Director, 10% Owner - [D] [O] [10%]  94,124,319 94,124,319
Fatih Uckun Chief Medical Officer, 10% Owner - [O] [10%]  2,985,484 2,985,484
Alastair JJ Wood  890 
Scott Young Chief Operating Officer - [O]  6,666 6,666

$OTLC other insiders

8,191,162 8,191,162
David Louis Johnson  0 
Mark Kessel Director, 10% Owner - [D] [10%]  5,835,241 5,835,241
Insider Avg Profit (%) Shares
Owned Split
Adjusted
Steven W King Director - [D]  3,330,647 3,330,647
Arthur B Laffer  10,000 
Peter Langecker Chief Executive Officer, Director - [D] [O]  77,993 77,993
Matthew M Loar Chief Financial Officer - [O]  300,000 300,000
Anthony E Iii Maida CHIEF CLINICAL OFFICER, Director - [D] [O]  1,137,314 1,137,314
Gerald PhD McMahon Director - [D]  18,611 18,611
Chulho Park CHIEF TECHNOLOGY OFFICER - [O]  2,833,992 2,833,992
Simon Pedder  258,171 
Barbara Riching  150,000 
Donald Rogers Reynolds Director - 280,000

$OTLC how is scammer Trieu going to pay all the convertible notes coming due?????  Time to create another bs company like he has done in the past.  Just pays this one lame company for pumper articles while he desperately tries to find another sucker to raise cash on.

$OTLC Trieu tried crypto poop coins now trying to throw AI into every paid pump article.  The guy is a dirt bag, nothing but failure.  Shareholders need to sue, its a fake company that does NOTHING

$OTLC so obvious when Dr Dumb Dumb starts paying for pumper posts and articles when the stock is dying.....nobody gonna buy his bs now to raise money...DEAD

Feed

News

Sentiment

Fundamentals

Info

OTLC Oncotelic Therapeutics Inc

Fundamentals

Latest OTLC News